Assignee
NEUTROLIS INC
US·11 granted patents·13 pending applications·18 citations·filing 2018–2024
Top patents by PatentIndex Score
24 records- 0190US10696956B2Engineered DNase enzymes and use in therapyNEUTROLIS INC·Filed 2019·Granted Jun 30, 2020·8 cites·25 claims
- 0286US10988746B2Manufacturing and engineering of DNASE enzymes for therapyNEUTROLIS INC·Filed 2019·Granted Apr 27, 2021·5 cites·16 claims
- 0382US11464833B2Methods for treating or preventing tissue adhesionsNEUTROLIS INC·Filed 2018·Granted Oct 11, 2022·3 cites·10 claims
- 0482US11046942B2DNase therapy for intravascular accumulation of extracellular DNANEUTROLIS INC·Filed 2020·Granted Jun 29, 2021·1 cites·22 claims
- 0581US10801019B1Engineered DNase enzymes and use in therapyNEUTROLIS INC·Filed 2020·Granted Oct 13, 2020·1 cites·21 claims
- 0679US2025129347A1Engineered human extracellular dnase enzymesNEUTROLIS INC·Filed 2024·Application pending·0 cites
- 0777US12565642B2Engineered DNASE enzymes for thrombosis therapyNEUTROLIS INC·Filed 2023·Granted Mar 3, 2026·0 cites·24 claims
- 0877US2024368569A1Engineered human extracellular dnase enzymes for drug candidate selectionNEUTROLIS INC·Filed 2024·Application pending·0 cites
- 0976US2024401015A1Dnase enzymes engineered for improved stabilityNEUTROLIS INC·Filed 2024·Application pending·0 cites
- 1075US2024374643A1Dnase1-like 3 and its use in therapyNEUTROLIS INC·Filed 2024·Application pending·0 cites
- 1173US11352613B2Engineered human extracellular DNASE enzymesNEUTROLIS INC·Filed 2021·Granted Jun 7, 2022·0 cites·30 claims
- 1271US11046943B2DNase therapy for intravascular accumulation of extracellular DNANEUTROLIS INC·Filed 2020·Granted Jun 29, 2021·0 cites·23 claims
- 1371US2025179451A1Dnase enzymes engineered for improved stabilityNEUTROLIS INC·Filed 2023·Application pending·0 cites
- 1471US2022259579A1Engineered human extracellular dnase enzymesNEUTROLIS INC·Filed 2022·Application pending·0 cites
- 1570US2021277372A1Engineered dnase enzymes and use in therapyNEUTROLIS INC·Filed 2021·Application pending·0 cites
- 1667US11578314B2Engineering of DNASE enzymes for manufacturing and therapyNEUTROLIS INC·Filed 2022·Granted Feb 14, 2023·0 cites·24 claims
- 1766US11840712B2Engineering of DNASE enzymes for manufacturing and therapyNEUTROLIS INC·Filed 2021·Granted Dec 12, 2023·0 cites·19 claims
- 1864US2022132817A1Animal model for drug developmentNEUTROLIS INC·Filed 2022·Application pending·0 cites
- 1963US11058724B2Methods of using DNASE1-like 3 in therapyNEUTROLIS INC·Filed 2020·Granted Jul 13, 2021·0 cites·18 claims
- 2063US2021299178A1Methods of using dnase1-like 3 in therapyNEUTROLIS INC·Filed 2021·Application pending·0 cites
- 2162US2023302097A1Methods for treating or preventing tissue adhesionsNEUTROLIS INC·Filed 2022·Application pending·0 cites
- 2262US2022025343A1Engineered human extracellular dnase enzymes for drug candidate selectionNEUTROLIS INC·Filed 2020·Application pending·0 cites
- 2358US2024228995A9Dnase 1-like 2 engineered for manufacturing and use in therapyNEUTROLIS INC·Filed 2022·Application pending·0 cites
- 2457US2023072226A1Basic domain-deleted dnase1-like 3 and uses thereofNEUTROLIS INC·Filed 2021·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →